1. Home
  2. DSGN vs CFFI Comparison

DSGN vs CFFI Comparison

Compare DSGN & CFFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • CFFI
  • Stock Information
  • Founded
  • DSGN 2017
  • CFFI 1927
  • Country
  • DSGN United States
  • CFFI United States
  • Employees
  • DSGN N/A
  • CFFI N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • CFFI Major Banks
  • Sector
  • DSGN Health Care
  • CFFI Finance
  • Exchange
  • DSGN Nasdaq
  • CFFI Nasdaq
  • Market Cap
  • DSGN 264.4M
  • CFFI 249.4M
  • IPO Year
  • DSGN 2021
  • CFFI 1998
  • Fundamental
  • Price
  • DSGN $5.57
  • CFFI $74.92
  • Analyst Decision
  • DSGN Hold
  • CFFI
  • Analyst Count
  • DSGN 3
  • CFFI 0
  • Target Price
  • DSGN $7.00
  • CFFI N/A
  • AVG Volume (30 Days)
  • DSGN 142.1K
  • CFFI 8.6K
  • Earning Date
  • DSGN 11-07-2024
  • CFFI 10-29-2024
  • Dividend Yield
  • DSGN N/A
  • CFFI 2.31%
  • EPS Growth
  • DSGN N/A
  • CFFI N/A
  • EPS
  • DSGN N/A
  • CFFI 5.66
  • Revenue
  • DSGN N/A
  • CFFI $114,783,000.00
  • Revenue This Year
  • DSGN N/A
  • CFFI N/A
  • Revenue Next Year
  • DSGN N/A
  • CFFI N/A
  • P/E Ratio
  • DSGN N/A
  • CFFI $13.17
  • Revenue Growth
  • DSGN N/A
  • CFFI N/A
  • 52 Week Low
  • DSGN $2.13
  • CFFI $33.51
  • 52 Week High
  • DSGN $7.77
  • CFFI $76.13
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 47.80
  • CFFI 70.39
  • Support Level
  • DSGN $5.32
  • CFFI $71.04
  • Resistance Level
  • DSGN $7.77
  • CFFI $75.00
  • Average True Range (ATR)
  • DSGN 0.58
  • CFFI 2.84
  • MACD
  • DSGN -0.09
  • CFFI 0.59
  • Stochastic Oscillator
  • DSGN 19.12
  • CFFI 92.59

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About CFFI C&F Financial Corporation

C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum revenue from the Community Banking segment.

Share on Social Networks: